|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| Commercialisation of Stem Cells Technologies | ||||||||||||||||
| June 19, 2002 | ||||||||||||||||
|
marcus evans, Central London, UK 200-09-19 |
||||||||||||||||
| Organized by: | marcus evans | |||||||||||||||
| Invited Speakers: | Peter Moutford, Chief Executive Officer, STEM CELL SCIENCES LTD. Hermann Graf, Head of Cell Therapy Research and Development, SBU Therapeutics, SCHERING AG. Martin Mc Glynn, President and Chief Executive Officer, STEMCELLS INC.. Susan Kingsman, Executive Director and Senior Vice President, Research, OXFORD BIOMEDICA PLC. Ole Madsen, Director of Hagedorn Research Institute, NOVO NORDISK. Tim Allsopp, Prinicipal Scientist, STEM CELL SCIENCES LTD. Julia L.Greenstein, Chief Executive Officer and President, IMMERGE BIOTHERAPEUTICS INC.. Douglas Armstrong, President, AASTROM BIOSCIENCES INC.. John Sinden, Chief Scientific Officer, RENEURON. Line Mattiessen, Principal Scientific Officer, EUROPEAN COMMISSION, DG RESEARCH. Jan Carlstedt-Duke, Professor of Molecular Endocrinology, Dean of Research, KAROLINSKA INSTITUTET. Dian McLaren, Strategy and Inititatives Co-ordinator, MEDICAL RESEARCH COUNCIL. Jan Willem Gratama, Board Member, EUROPEAN WORKING GROUP ON CLINICAL CELL ANALYSIS. Elisabeth Rynning, Associate Professor in Public Law, UPPSALA UNIVERSITY. Glyn Stacey, Head of Cell Biology, NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL. Lars Hamberger, Department of Obstetrics and Gynaecology, GÖTEBORG UNIVERSITY . Peter Wernet, Director, Institute of Transplantation and Cell Therapies, UNIVERSITY OF DÜSSELDORF. |
|||||||||||||||
| Deadline for Abstracts: | ||||||||||||||||
| Registration: | ||||||||||||||||
| E-mail: | olas@marcusevansuk.com | |||||||||||||||
| Posted by: | Ola Samuelsson | |||||||||||||||
| Host: | 194.74.216.2 | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||